Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ATP4A | P20648 | 5/20 | 0.48 |
| ▸ | ATP4B | P51164 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9753950 | 0.79 | ALDH1A1 (0.39) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10921468 | 0.77 | ATP4A (0.51) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13176306 | 0.76 | CYP1A2 (0.58) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8608835 | 0.74 | SMN1; SMN2 (0.48) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6358896 | 0.74 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18800987 | 0.74 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10751414 | 0.74 | CYP1A2 (0.47) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10921260 | 0.74 | ATP4A (0.53) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL6355106 | 0.73 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5220990 | 0.73 | ATP4A (0.51) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154007-A1 | New compounds | AMIN KOSRAT (SE) | 2005-07-14 | — | — | US | disclosed |
| US-6790960-B2 | Compounds | ASTRAZENECA AB (SE) | 2004-09-14 | — | — | US | disclosed |
| EP-1411056-A2 | Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for their preparation | AstraZeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030220364-A1 | New compounds | AMIN KOSRAT (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6579884-B1 | Compounds | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| EP-1105391-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011000-A2 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220364-A1 | New compounds | SLC10A2, GIPR, FABP2 | CYP3A4 2404/4885CYP2C9 3074/4885CYP1A2 1919/4885 |
| US-20050154007-A1 | New compounds | SLC10A2, GIPR, FABP6 | CYP3A4 2475/4885CYP2C9 3139/4885CYP1A2 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.